Skip to main content
Drugwatch.com
  • Active Lawsuits
    • Lawsuits Directory
      • Prescription Drug Lawsuits
        • Depo-Provera Lawsuit
        • Dupixent Lawsuit
        • Ozempic Lawsuit
        • Suboxone Lawsuit
        • Wegovy Lawsuit
      • Product Lawsuits
        • Baby Formula NEC Lawsuit
        • Hair Dye Lawsuit
        • Hair Relaxer Lawsuit
        • Social Media Addiction Lawsuit
      • Medical Device Lawsuits
        • Bard PowerPort Lawsuit
        • Hernia Mesh Lawsuit
        • Hip Replacement Lawsuit
        • Olympus Scope Lawsuit
        • Transvaginal Mesh Lawsuit
      • Chemical Exposure Lawsuits
        • Chlorpyrifos Lawsuit
        • Paraquat Lawsuit
        • Roundup Lawsuit
    • Injured by a prescription drug or defective medical device?
      Get a Free Case Review
  • Latest Legal News
    • News
    • Latest News
      FDA Adds Vision Loss Warning to All GLP-1 Drugs, Including Ozempic, Wegovy and Mounjaro
      November 9, 2026
      Latest News
      L’Oréal Faces New Lawsuit from Minnesota Over Hair Relaxer Cancer Concerns
      October 26, 2026
      Latest News
      Compounded GLP-1 Injections Recalled Over Sterility Issues
      October 22, 2026
    • Drugwatch Investigations
    • Featured Article
      Plastic Surgeons Are Telling Patients That Breast Mesh Is FDA Approved. It Isn’t.
    • Plaintiff Stories
    • Latest Story
      After Breast Cancer, Scientist Wants Women to Know Mirena’s Risks
  • High-Risk Drugs & Devices
    • Drugs
      • Depo-Provera
      • Dupixent
      • Mounjaro (Tirzepatide)
      • Ozempic (Semaglutide)
      • Tepezza
      • Truvada
      • Tylenol (Acetaminophen)
    • Devices
      • Allergan Breast Implants
      • Bard PowerPort
      • FreeStyle Libre Sensors
      • Hernia Mesh
      • Hip Replacements
      • IVC Filters
      • Olympus Scopes
      • Paragard
      • Spinal Cord Stimulators
      • Transvaginal Mesh
  • Who We Are
    • About Drugwatch
      • Our Team
        • Awards & Accreditations
        • Client Reviews
        • Video Library
      • Our Trusted Legal Partners
        • Attorney Q&As
        • Drugwatch Editorial Policy
        • Press Room
    • Our Legal Experts
      • Brendan McDonough, Weitz & Luxenberg attorney
        Brendan A. McDonough, Esquire Associate Attorney, Drug & Medical Device Litigation
      • Headshot of attorney Jonathan Sedgh
        Jonathan M. Sedgh, Esquire Mass Tort & Product Liability Attorney
      • Jayne Conroy, Named Shareholder of Simmons Hanly Conroy
        Jayne Conroy, Esquire Trial Attorney and Pharmaceutical Litigation Expert
      • Headshot of attorney, Trent Miracle.
        Trent B. Miracle, Esquire Mass Tort and Product Liability Attorney
SPEAK WITH AN EXPERT
Call Now (888) 645-1617 Who Am I Calling?
(888) 645-1617Call Now
click to open search box
Brought To You By The Wilson Firm LLP

News

Elmiron Pill
Attorney Q&As Elmiron & Vision Problems Lawsuits: A Q&A with Trial Attorney Trent Miracle
Elmiron, or pentosan polysulfate sodium, is the only oral medication approved by the U.S. Food and Drug Administration to treat interstitial cystitis. IC is a chronic condition that causes bladder pain and pressure. About three to eight million women and one to four million men in the…
September 25, 2020
Read More
  • Stanford Professor Bonnie Halpern-Felsher
    COVID-19 and Vaping: A Q&A with Stanford Professor Bonnie Halpern-Felsher
    September 15, 2020
  • Michelle Llamas
    Drugwatch Writer Helps Secure Funding for National COVID-19 Teleconference
    September 1, 2020
  • White House
    Presidential Election 2020: Health Care and Drug Prices
    August 24, 2020
  • Patient using IV drip
    Thousands of Infusion Pumps Recalled After Several Injuries and a Death
    August 3, 2020
  • Braint stent
    Ten Injuries and One Death Lead to Medtronic Brain Stent Recall
    July 27, 2020
  • Medtronic office building
    Medtronic Recalls Heart Pumps After Patient Death
    July 6, 2020
  • Methotrexate tablets
    Rheumatoid Arthritis Drug Methotrexate Linked to Increased Skin Cancer Risk
    June 22, 2020
  • Talcum powder with cross
    Johnson & Johnson Stops Selling Talc-Based Baby Powder in U.S.
    May 20, 2020
Previous
  • 1
  • …
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • …
  • 94
Next

Featured Articles

More
  • Plastic Surgeons Are Telling Patients That Breast Mesh Is FDA Approved. It Isn’t.
    November 9, 2026
  • Big Tech on Trial: Inside the Social Media Addiction Lawsuits
    June 29, 2026
  • Survey Finds 45% of Americans Misread Drug Labels
    May 21, 2026

Personal Stories

More
  • After Breast Cancer, Scientist Wants Women to Know Mirena’s Risks
    October 1, 2026
  • Former Nurse Left Disabled After Exactech Shoulder Implant Failure
    September 10, 2026
  • Missouri Man’s Life Forever Changed After Using Common Antibiotic
    September 3, 2026
Who Am I Calling?

Calling this number connects you with a Drugwatch.com representative. We will direct you to one of our trusted legal partners for a free case review.

Drugwatch.com's trusted legal partners support the organization's mission to keep people safe from dangerous drugs and medical devices. For more information, visit our partners page.

(888) 645-1617
Get A Free Case Review

Injured by a drug, medical device or product? You may be entitled to compensation. Speak with an experienced attorney at no cost or obligation.

See If You QualifySee If You Qualify
Navigate
  • Lawsuits
  • FDA
  • News
  • Drugs
  • About Us
  • Health Info
  • Devices
  • Drugwatch Podcast
  • Side Effects
  • Beyond Side Effects
Drugwatch.com

Help for people injured by defective drugs and medical devices

More About Us
  • (888) 645-1617 Who Am I Calling?
  • Connect with Drugwatch on Facebook
  • Connect with Drugwatch on Twitter
  • Connect with Drugwatch on Youtube
  • Contact Drugwatch by Email
  • Click for the BBB Business Review of Drugwatch.com, LLC
  • AMWA Member Logo
  • APHA Logo
  • AACI Logo

Drugwatch is located at:
1 South Orange Ave, Suite 201, Orlando, FL 32801

The information on this website is proprietary and protected. It is not a substitute for advice, diagnosis, treatment and other oversight responsibilities for disease processes by a credentialed physician. Any unauthorized or illegal use, copying or dissemination will be prosecuted. Please read our disclaimer for more information about our website.

Drugwatch.com partners with law firms. This website and its content may qualify as attorney advertising. Prior results do not predict a similar outcome. For more information, visit our partners page.

© 2026 Drugwatch.com Privacy Policy /

California Consumer Privacy Act (CCPA) Inquiries

Drugwatch.com doesn’t believe in selling customer information. However, as required by the new California Consumer Privacy Act (CCPA), you may record your preference to view or remove your personal information by completing the form below.

Sorry there was an error. Please wait a moment and try again.
Sorry there is a continuing error in our system. Please call us using the phone number listed on this page.

We value your privacy. By clicking REVIEW MY CASE, you agree to our privacy policy and disclaimer. After submitting, you will be contacted by one or more of Drugwatch's trusted legal partners (including autodialed and prerecorded calls or text/SMS messages). Msg. and data rates apply. Your consent to text messaging is not required for a case review and you may opt out of text messages at any time by texting STOP. This is legal advertising.

Your web browser is no longer supported by Microsoft. Update your browser for more security, speed and compatibility.

If you would like to speak with a Drugwatch representative, please call 888-645-1617